AR078326A1 - Quinazolinas como inhibidores de los canales ionicos de potasio y composiciones farmaceuticas que los contienen - Google Patents
Quinazolinas como inhibidores de los canales ionicos de potasio y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR078326A1 AR078326A1 ARP100103247A ARP100103247A AR078326A1 AR 078326 A1 AR078326 A1 AR 078326A1 AR P100103247 A ARP100103247 A AR P100103247A AR P100103247 A ARP100103247 A AR P100103247A AR 078326 A1 AR078326 A1 AR 078326A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- cycloalkyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Los compuestos son utiles como inhibidores de la funcion de los canales de potasio y en el tratamiento y prevencion de arritmia, trastornos asociados con IKur y otros trastornos mediados por la funcion de los canales ionicos. Reivindicacion 1: Un compuesto, caracterizado porque tiene la formula (1) o un enantiomero, diastereomero, tautomero o sales del mismo, en la que: X es H, -OH, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, alquenilo C2-12 alquinilo C2-12, cicloalquilo C3-10, un heteroarilo de 4 a 12 miembros, heterociclilo de 4 a 12 miembros, -CN, -NO2, -NR11SO2R12, -SO2NR11R12, -CONR11R12, -NR11CONR11R12, -NCOR11, -NR11SO2NR11R12, -OCONR11R12, -CO2R11 o -NR11R12; Y es H, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, alquenilo C2-12, alquinilo C2-12, cicloalquilo C3-10, un heteroarilo de 4 a 12 miembros, heterociclilo de 4 a 12 miembros, -CN, -NO2, -SO2NR11R12, -CONR11R12, -NR11CONR11R12, -NCOR11, -NR11SO2NR11R12, -OCONR11R12, -CO2R11 o -NR11R12; Z es H, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, alquenilo C2-12, alquinilo C2-12, cicloalquilo C3-10, un heteroarilo de 6 a 12 miembros, heterociclilo de 4 a 12 miembros, -NO2, -NR11SO2R12, -SO2NR11R12, -NR11CONR11R12, -NCOR11, -NR11SO2NR11R12, -OCONR11R12, -CO2R11 o -NR11R12; A es -(CH2)m-R2, -CH(R25)(R26), -CH(R26)CO2-R2a o -(CH2)n-1-NR25-CO2-R24; m es 0 a 4; n es 1 a 4; n-1 es 2 a 4; R1 es -OH, F, Cl, Br, I, alquilo C1-10, haloalquilo C1-10, alquenilo C2-12, cicloalquilo C3-10, -CN, -(CH2)n-SO2NR11R12, -(CH2)n-CO2R11 o -(CH2)n-NR11SO2R12, pudiendo estar el alquenilo y cicloalquilo opcionalmente sustituidos con uno o más R13; o R1 se selecciona del grupo de formulas (2); o R1 es el resto de formula (3); R2 es alquilo C1-10, ciclopropilo opcionalmente sustituido con uno o más R13; cicloalquilo C4-10 opcionalmente sustituido con uno o más R13bb; cicloalquenilo C3-10 opcionalmente sustituido con uno o más R13b; o -NR14R14; con la condicion de que R2 no sea -NR14R14 cuando m sea 0, 1 o 3; o R2 es el resto de formula (4); o R2 se selecciona del grupo de formulas (5); R2a es alquilo C1-10, cicloalquilo C3-10, arilo C6-10, -NR14R14, un heteroarilo de 4 a 12 miembros o heterociclilo de 4 a 12 miembros, cualquiera de los cuales está opcionalmente sustituido con uno o más R13 y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R11 y R12, en cada aparicion, se seleccionan independientemente de H, alquilo C1-10, haloalquilo C1-10, cicloalquilo C3-10, arilo C6-10, un heteroarilo de 4 a 12 miembros y un heterociclilo de 4 a 12 miembros, pudiendo estar el alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R13 y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; o R11 y R12 se toman junto con el nitrogeno al que están unidos formando un heterociclilo de 4 a 12 miembros, pudiendo estar el heterociclilo opcionalmente sustituido con uno o más R13 y el heterociclilo está constituido por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13, en cada aparicion, es independientemente H, -OH, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -CONR14R14, -(CH2)m-SO2NR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; con la condicion de que cuando R13 sea alquilo sustituido con un R14a, R14a no sea -OH; R13a, en cada aparicion, es independientemente H, -OH, F, Cl, Br, I, alquilo C2-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -CONR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13aa, en cada aparicion, es independientemente H, -OH, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -CONR14R14, -(CH2)m-SO2NR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13a-1, en cada aparicion, es independientemente H, -OH, F, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -CONR14R14, -(CH2)m-SO2NR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13a-2, en cada aparicion, es independientemente H, -OH, F, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -CONR14R14, -(CH2)m-SO2NR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13a-4, en cada aparicion, es independientemente H, -OH, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -CONR14R14, -(CH2)m-SO2NR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13b, en cada aparicion, es independientemente H, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un heterociclilo de 4 a 12 miembros, un heteroaril de 4 a 12 miembros-alquilo C1-10, -CN, -NO2, -(CH2)m-SO2R14, -NR14SO2R14, =O, -(CH2)m-SO2NR14R14, -(CH2)m-NR14SO2R14, -(CH2)n-NR14SO2NR14R14, -NR14SO2NR14R14, -CO2NR14R14, -NR14CO2NR14R14, -NR14COR14, -SO2NR14COR14, -SO2NR14CONR14R14, -NR14CO2R14, -CO2R14, -NR14R14, -NR14CONR14R14, -C(=NOR14)NR14R14, -CONR14OR14 o -NCOR14, pudiendo estar el alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo y heterociclilo opcionalmente sustituidos con uno o más R14a y el heteroarilo y heterociclilo están constituidos por átomos de carbono y 1, 2, 3 o 4 heteroátomos seleccionados independientemente del grupo constituido por N, S u O; R13bb, en cada aparicion, es independientemente H, F, Cl, Br, I, alquilo C1-10, alcoxi C1-10, haloalquilo C1-10, cicloalquilo C3-10, alquenilo C2-12, alquinilo C2-12, arilo C6-10, un heteroarilo de 4 a 12 miembros, un
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23945209P | 2009-09-03 | 2009-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078326A1 true AR078326A1 (es) | 2011-11-02 |
Family
ID=42942118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103247A AR078326A1 (es) | 2009-09-03 | 2010-09-03 | Quinazolinas como inhibidores de los canales ionicos de potasio y composiciones farmaceuticas que los contienen |
Country Status (32)
Country | Link |
---|---|
US (8) | US8575184B2 (es) |
EP (3) | EP3575288B1 (es) |
JP (2) | JP5643312B2 (es) |
KR (1) | KR101698631B1 (es) |
CN (1) | CN102753535B (es) |
AR (1) | AR078326A1 (es) |
AU (1) | AU2010289641B2 (es) |
BR (1) | BR112012008330B1 (es) |
CA (1) | CA2772642C (es) |
CL (1) | CL2012000583A1 (es) |
CO (1) | CO6511220A2 (es) |
CY (2) | CY1118488T1 (es) |
DK (2) | DK2473487T3 (es) |
EA (1) | EA021113B1 (es) |
ES (3) | ES2609335T3 (es) |
HR (2) | HRP20211973T1 (es) |
HU (2) | HUE032983T2 (es) |
IL (1) | IL218169A (es) |
LT (2) | LT2473487T (es) |
MX (1) | MX2012002099A (es) |
MY (1) | MY160243A (es) |
NZ (1) | NZ598516A (es) |
PE (1) | PE20121153A1 (es) |
PL (2) | PL3575288T3 (es) |
PT (2) | PT3575288T (es) |
SG (1) | SG178592A1 (es) |
SI (2) | SI3575288T1 (es) |
SM (1) | SMT201700026B (es) |
TN (1) | TN2012000063A1 (es) |
TW (1) | TWI488851B (es) |
WO (1) | WO2011028741A1 (es) |
ZA (1) | ZA201202383B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211973T1 (hr) * | 2009-09-03 | 2022-03-18 | Bristol-Myers Squibb Company | Kinazolini kao inhibitori ionskih kalijskih kanala |
AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
AR086798A1 (es) * | 2011-06-29 | 2014-01-22 | Otsuka Pharma Co Ltd | Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen |
CN103360382B (zh) * | 2012-03-26 | 2016-04-27 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及其用途 |
PE20150228A1 (es) * | 2012-06-11 | 2015-02-19 | Bristol Myers Squibb Co | Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida |
CN105143187B (zh) | 2013-02-28 | 2018-04-03 | 武田药品工业株式会社 | 制备磺酰氯化合物的方法 |
US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
EP2970295B1 (en) * | 2013-03-11 | 2016-12-28 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
WO2014143609A1 (en) | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
ES2616025T3 (es) * | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolotriazinas como inhibidores de canales de iones potasio |
US9242966B2 (en) * | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
JP6319317B2 (ja) * | 2013-10-17 | 2018-05-09 | 住友化学株式会社 | テトラゾリノン化合物及びその用途 |
CN106458904B (zh) | 2014-06-10 | 2021-12-03 | 宇部兴产株式会社 | N-取代磺酰胺化合物及其制造方法 |
CA2951790C (en) | 2014-06-10 | 2022-05-31 | Ube Industries, Ltd. | Method for producing heteroaromatic sulfonamide compound |
US10774072B2 (en) | 2014-06-10 | 2020-09-15 | Ube Industries, Ltd. | Crystal of N-substituted sulfonamide compound |
CA2969856A1 (en) | 2014-12-05 | 2016-06-09 | Subramaniam Ananthan | Novel quinazolines as biogenic amine transport modulators |
KR20170117023A (ko) * | 2014-12-05 | 2017-10-20 | 서브라마니암 아난탄 | 생체 아민 수송 조절인자로서 헤테로환상 화합물 |
CA2988637A1 (en) * | 2015-06-10 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives |
KR102388962B1 (ko) | 2016-05-03 | 2022-04-27 | 바이엘 파마 악티엔게젤샤프트 | 방향족 술폰아미드 유도체 |
CN106432067B (zh) * | 2016-09-18 | 2019-04-19 | 北京天弘天达医药科技有限公司 | 一种3-吡啶磺酰氯的绿色化学合成方法 |
MA50448A (fr) * | 2017-10-29 | 2020-09-02 | Bayer Ag | Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémique |
KR20210003154A (ko) * | 2018-04-20 | 2021-01-11 | 바이엘 악티엔게젤샤프트 | 살충제로서의 헤테로아릴-트리아졸 및 헤테로아릴-테트라졸 화합물 |
US20220227729A1 (en) | 2019-05-21 | 2022-07-21 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
WO2022058344A1 (en) | 2020-09-18 | 2022-03-24 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
WO2023212181A1 (en) * | 2022-04-28 | 2023-11-02 | University Of Miami | Compounds for proliferative disorders |
WO2024056782A1 (en) | 2022-09-16 | 2024-03-21 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
WO2024079252A1 (en) | 2022-10-13 | 2024-04-18 | Bayer Aktiengesellschaft | Sos1 inhibitors |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3843791A (en) | 1973-01-11 | 1974-10-22 | Pfizer | Method of killing insects with quinazolinones and quinazoline-thiones |
DE69221175T2 (de) | 1991-02-07 | 1998-01-15 | Roussel Uclaf | Bizyklische Stickstoffverbindungen, ihre Herstellung, erhaltene Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
DE69425804T2 (de) * | 1993-06-17 | 2001-02-08 | Otsuka Pharma Co Ltd | Phosphonsäurediesterderivate |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
JPH083144A (ja) | 1994-06-21 | 1996-01-09 | Chugai Pharmaceut Co Ltd | キナゾリン及びキノリン誘導体 |
TW414798B (en) | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
AU7692996A (en) * | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
AU7890598A (en) | 1996-12-27 | 1998-07-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
EP1014953B1 (en) | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
AU7301000A (en) | 1999-09-21 | 2001-04-24 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
CZ20021086A3 (cs) * | 1999-09-30 | 2002-10-16 | Neurogen Corporation | Alkylendiaminem substituované heterocykly |
AU2001245401A1 (en) | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
KR20030061807A (ko) | 2000-09-20 | 2003-07-22 | 메르크 파텐트 게엠베하 | 4-아미노-퀴나졸린 |
WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
WO2002062767A1 (fr) | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux derives de quinazoline |
WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
WO2004056801A1 (en) | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | Quinazoline derivatives |
WO2004056812A1 (en) | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
WO2004069145A2 (en) | 2003-02-07 | 2004-08-19 | Dr. Reddy's Laboratories Ltd. | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them |
ZA200507979B (en) * | 2003-03-03 | 2007-03-28 | Vertex Pharma Inc | Quinazolines useful as modulators of ion channels |
US7713983B2 (en) | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
WO2004087680A1 (en) | 2003-03-31 | 2004-10-14 | Taisho Pharmaceutical Co., Ltd. | Novel quinazoline derivatives and methods of treatment related to the use thereof |
ES2324536T7 (es) | 2003-06-11 | 2012-03-16 | Xention Limited | Derivados de tenopirimidina como inhibidores de los canales de potasio. |
CA2528774A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
AU2004253967B2 (en) | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
JP4719681B2 (ja) * | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | キナゾリンカリウムチャネル阻害剤 |
WO2005042501A1 (en) | 2003-11-03 | 2005-05-12 | Warner-Lambert Company Llc | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
JPWO2005087749A1 (ja) | 2004-03-15 | 2007-08-09 | 協和醗酵工業株式会社 | 2−アミノキナゾリン誘導体 |
JP4955557B2 (ja) | 2004-06-10 | 2012-06-20 | ゼンション・リミテッド | カリウムチャネル阻害剤として有効なフラノピリミジン化合物 |
US20060014705A1 (en) | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
EP1768964A1 (en) | 2004-07-06 | 2007-04-04 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
ATE476434T1 (de) | 2004-12-09 | 2010-08-15 | Xention Ltd | Thienopyridinderivate als kaliumkanalinhibitoren |
JP2008526734A (ja) | 2004-12-31 | 2008-07-24 | エスケー ケミカルズ カンパニー リミテッド | 糖尿及び肥満治療予防に有効なキナゾリン誘導体 |
EP1853302A2 (en) | 2005-02-18 | 2007-11-14 | Novartis Vaccines and Diagnostics, Inc. | Antiangiogenic agents with aldesleukin |
MX2007010991A (es) | 2005-03-14 | 2007-11-07 | Neurosearch As | Agentes que modulan el canal de potasio y su uso medico. |
WO2006099972A1 (en) | 2005-03-23 | 2006-09-28 | F. Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
CA2602294C (en) | 2005-03-25 | 2015-02-24 | Tibotec Pharmaceuticals Ltd. | Heterobicylic inhibitors of hvc |
CN101189234B (zh) | 2005-03-25 | 2011-08-17 | 泰博特克药品有限公司 | Hcv的杂二环抑制剂 |
EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
US20070049559A1 (en) | 2005-06-28 | 2007-03-01 | Bruce Pfeffer | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
JP2009519995A (ja) | 2005-12-20 | 2009-05-21 | ノイロサーチ アクティーゼルスカブ | 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての2−ピリジン−2−イル−キナゾリン誘導体 |
CN101360738A (zh) | 2005-12-21 | 2009-02-04 | 佩因赛普托药物公司 | 调节门控离子通道的组合物和方法 |
DE102006012251A1 (de) | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
EP2589597B1 (en) | 2006-08-22 | 2019-03-06 | Technion Research & Development Foundation | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) |
WO2008030120A1 (en) | 2006-09-07 | 2008-03-13 | Auckland Uniservices Limited | A method for the fluorescent detection of nitroreductase activity using nitro-substituted aromatic compounds |
WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害剤としてのナフチリジン誘導体 |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
WO2009006141A2 (en) | 2007-07-05 | 2009-01-08 | Bausch & Lomb Incorporated | Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
CN101575333B (zh) | 2008-05-09 | 2011-06-22 | 和记黄埔医药(上海)有限公司 | 一种喹唑啉衍生物及其医药用途 |
US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
AU2009249106A1 (en) | 2008-05-21 | 2009-11-26 | Genentech, Inc. | Arylsulfonamide compounds, compositions and methods of use |
HRP20211973T1 (hr) * | 2009-09-03 | 2022-03-18 | Bristol-Myers Squibb Company | Kinazolini kao inhibitori ionskih kalijskih kanala |
EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
-
2010
- 2010-09-01 HR HRP20211973TT patent/HRP20211973T1/hr unknown
- 2010-09-01 SI SI201032099T patent/SI3575288T1/sl unknown
- 2010-09-01 DK DK10754824.0T patent/DK2473487T3/en active
- 2010-09-01 TW TW099129546A patent/TWI488851B/zh active
- 2010-09-01 MY MYPI2012000987A patent/MY160243A/en unknown
- 2010-09-01 PL PL19186129T patent/PL3575288T3/pl unknown
- 2010-09-01 KR KR1020127008470A patent/KR101698631B1/ko active IP Right Grant
- 2010-09-01 DK DK19186129.3T patent/DK3575288T3/da active
- 2010-09-01 PE PE2012000290A patent/PE20121153A1/es active IP Right Grant
- 2010-09-01 HU HUE10754824A patent/HUE032983T2/en unknown
- 2010-09-01 CA CA2772642A patent/CA2772642C/en active Active
- 2010-09-01 CN CN201080049632.7A patent/CN102753535B/zh active Active
- 2010-09-01 PT PT191861293T patent/PT3575288T/pt unknown
- 2010-09-01 ES ES10754824.0T patent/ES2609335T3/es active Active
- 2010-09-01 ES ES16180810T patent/ES2750598T3/es active Active
- 2010-09-01 HU HUE19186129A patent/HUE057433T2/hu unknown
- 2010-09-01 JP JP2012527985A patent/JP5643312B2/ja active Active
- 2010-09-01 BR BR112012008330-9A patent/BR112012008330B1/pt active IP Right Grant
- 2010-09-01 WO PCT/US2010/047430 patent/WO2011028741A1/en active Application Filing
- 2010-09-01 US US13/393,328 patent/US8575184B2/en active Active
- 2010-09-01 NZ NZ598516A patent/NZ598516A/xx unknown
- 2010-09-01 SI SI201031326T patent/SI2473487T1/sl unknown
- 2010-09-01 AU AU2010289641A patent/AU2010289641B2/en active Active
- 2010-09-01 PL PL10754824T patent/PL2473487T3/pl unknown
- 2010-09-01 EP EP19186129.3A patent/EP3575288B1/en active Active
- 2010-09-01 LT LTEP10754824.0T patent/LT2473487T/lt unknown
- 2010-09-01 ES ES19186129T patent/ES2900504T3/es active Active
- 2010-09-01 PT PT107548240T patent/PT2473487T/pt unknown
- 2010-09-01 EP EP10754824.0A patent/EP2473487B1/en active Active
- 2010-09-01 SG SG2012013918A patent/SG178592A1/en unknown
- 2010-09-01 EA EA201270378A patent/EA021113B1/ru not_active IP Right Cessation
- 2010-09-01 MX MX2012002099A patent/MX2012002099A/es active IP Right Grant
- 2010-09-01 LT LTEP19186129.3T patent/LT3575288T/lt unknown
- 2010-09-01 EP EP16180810.0A patent/EP3124475B1/en active Active
- 2010-09-03 AR ARP100103247A patent/AR078326A1/es active IP Right Grant
-
2012
- 2012-02-10 TN TNP2012000063A patent/TN2012000063A1/en unknown
- 2012-02-16 IL IL218169A patent/IL218169A/en active IP Right Grant
- 2012-03-02 CL CL2012000583A patent/CL2012000583A1/es unknown
- 2012-03-07 CO CO12040232A patent/CO6511220A2/es active IP Right Grant
- 2012-04-02 ZA ZA2012/02383A patent/ZA201202383B/en unknown
-
2013
- 2013-09-27 US US14/038,814 patent/US9458114B2/en active Active
-
2014
- 2014-10-30 JP JP2014221908A patent/JP5950978B2/ja active Active
-
2016
- 2016-08-29 US US15/249,710 patent/US9822096B2/en active Active
- 2016-12-08 HR HRP20161669TT patent/HRP20161669T1/hr unknown
-
2017
- 2017-01-16 SM SM201700026T patent/SMT201700026B/it unknown
- 2017-01-23 CY CY20171100095T patent/CY1118488T1/el unknown
- 2017-10-04 US US15/724,566 patent/US10214511B2/en active Active
-
2019
- 2019-01-09 US US16/243,400 patent/US10676460B2/en active Active
-
2020
- 2020-05-01 US US16/864,825 patent/US11008306B2/en active Active
-
2021
- 2021-04-15 US US17/231,088 patent/US20220324836A1/en not_active Abandoned
- 2021-12-16 CY CY20211101107T patent/CY1125021T1/el unknown
-
2023
- 2023-03-24 US US18/125,826 patent/US20230322726A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078326A1 (es) | Quinazolinas como inhibidores de los canales ionicos de potasio y composiciones farmaceuticas que los contienen | |
MX2014015501A (es) | Carboxamidas heterociclicas fungicidas. | |
AR086587A1 (es) | Compuestos insecticidas | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
ECSP11010912A (es) | Compuestos de pirrol | |
EA201591775A1 (ru) | Замещенные ароматические соединения и связанный с ними способ лечения фиброза | |
AR095208A1 (es) | Pirrolotriazinas como inhibidores del canal del ión potasio | |
ES2539722T3 (es) | Compuesto de tetrahidrobenzotiofeno | |
PE20181039A1 (es) | Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
JP2016540742A5 (es) | ||
CY1122470T1 (el) | Αναστολεις kv1.3 και η ιατρικη εφαρμογη αυτων | |
EA201690879A1 (ru) | Новое триазолопиридиновое соединение | |
AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
PE20141201A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
EA201891770A1 (ru) | Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм | |
EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты | |
AR059886A1 (es) | Derivados de amidas como inhibidores de renina | |
MY182353A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
JP2017513852A5 (es) | ||
CY1115635T1 (el) | Παραγωγα 2-πυριδιν-2-υλο-πυραζολ-3(2η)-ονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη | |
EA201692063A1 (ru) | Спиросоединения мочевины в качестве противовирусных соединений против rsv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |